Exp Neurobiol.  2017 Aug;26(4):186-194. 10.5607/en.2017.26.4.186.

Toll-like Receptor 2: A Novel Therapeutic Target for Ischemic White Matter Injury and Oligodendrocyte Death

Affiliations
  • 1Department of Neurology, Ajou University School of Medicine, Suwon 16499, Korea. kimbg@ajou.ac.kr
  • 2Department of Brain science, Ajou University School of Medicine, Suwon 16499, Korea.

Abstract

Despite paramount clinical significance of white matter stroke, there is a paucity of researches on the pathomechanism of ischemic white matter damage and accompanying oligodendrocyte (OL) death. Therefore, a large gap exists between clinical needs and laboratory researches in this disease entity. Recent works have started to elucidate cellular and molecular basis of white matter injury under ischemic stress. In this paper, we briefly introduce white matter stroke from a clinical point of view and review pathophysiology of ischemic white matter injury characterized by OL death and demyelination. We present a series of evidence that Toll-like receptor 2 (TLR2), one of the membranous pattern recognition receptors, plays a cell-autonomous protective role in ischemic OL death and ensuing demyelination. Moreover, we also discuss our recent findings that its endogenous ligand, high-mobility group box 1 (HMGB1), is released from dying OLs and exerts autocrine trophic effects on OLs and myelin sheath under ischemic condition. We propose that modulation of TLR2 and its endogenous ligand HMGB1 can be a novel therapeutic target for ischemic white matter disease.

Keyword

Oligodendrocyte; White matter; Ischemia; Toll-like receptor 2; High-mobility group box 1

MeSH Terms

Demyelinating Diseases
HMGB1 Protein
Ischemia
Leukoencephalopathies
Myelin Sheath
Oligodendroglia*
Receptors, Pattern Recognition
Stroke
Toll-Like Receptor 2*
Toll-Like Receptors*
White Matter*
HMGB1 Protein
Receptors, Pattern Recognition
Toll-Like Receptor 2
Toll-Like Receptors
Full Text Links
  • EN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr